Rasmus Sorrig

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: December 02, 2025

Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.

Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.

Journal: Obesity (Silver Spring, Md.)

Published: March 30, 2023

A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.

A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.

Journal: Diabetes, obesity & metabolism

Published: March 30, 2023

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.

Journal: Journal of comparative effectiveness research

Published: December 19, 2022

Once-Weekly Semaglutide in Adolescents with Obesity.

Once-Weekly Semaglutide in Adolescents with Obesity.

Journal: The New England journal of medicine

Published: November 02, 2022

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.

Journal: Diabetes care

Published: September 28, 2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Journal: JAMA

Published: January 11, 2022

Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.

Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.

Journal: British journal of haematology

Published: March 29, 2020

Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study.

Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 07, 2019

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.

Journal: Diabetes, obesity & metabolism

Published: September 30, 2019

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.

Journal: European journal of haematology

Published: August 13, 2018

Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark.

Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark.

Journal: European journal of haematology

Published: February 19, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026